XENON XE-129 HYPERPOLARIZED - Generic Drug Details

What are the generic drug sources for xenon xe-129 hyperpolarized and what is the scope of freedom to operate?

Xenon xe-129 hyperpolarized is the generic ingredient in one branded drug marketed by Polarean and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Xenon xe-129 hyperpolarized has six patent family members in six countries.

One supplier is listed for this compound.

Summary for XENON XE-129 HYPERPOLARIZED

International Patents:	6
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	113
DailyMed Link:	XENON XE-129 HYPERPOLARIZED at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XENON XE-129 HYPERPOLARIZED

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

GAS;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XENON XE-129 HYPERPOLARIZED

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
M.D. Anderson Cancer Center	EARLY_PHASE1
Sean Fain	PHASE2
Yuh Chin T Huang, MD, MHS	PHASE1

See all XENON XE-129 HYPERPOLARIZED clinical trials

Pharmacology for XENON XE-129 HYPERPOLARIZED

Drug Class	Hyperpolarized Contrast Agent
Mechanism of Action	Magnetic Resonance Contrast Activity

Anatomical Therapeutic Chemical (ATC) Classes for XENON XE-129 HYPERPOLARIZED

N01AX	Other general anesthetics
N01A	ANESTHETICS, GENERAL
N01	ANESTHETICS
N	Nervous system

V04CX	Other diagnostic agents
V04C	OTHER DIAGNOSTIC AGENTS
V04	DIAGNOSTIC AGENTS
V	Various

US Patents and Regulatory Information for XENON XE-129 HYPERPOLARIZED

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Polarean	XENOVIEW	xenon xe-129 hyperpolarized	GAS;INHALATION	214375-001	Dec 23, 2022		RX	Yes	Yes
Polarean	XENOVIEW	xenon xe-129 hyperpolarized	GAS;INHALATION	214375-001	Dec 23, 2022		RX	Yes	Yes			Y
Polarean	XENOVIEW	xenon xe-129 hyperpolarized	GAS;INHALATION	214375-001	Dec 23, 2022		RX	Yes	Yes			Y

International Patents for XENON XE-129 HYPERPOLARIZED

Country	Patent Number	Title	Estimated Expiration
Hungary	E045999
European Patent Office	3107583
World Intellectual Property Organization (WIPO)	2015127208

Market Dynamics and Financial Trajectory for XENON XE-129 Hyperpolarized

Last updated: February 20, 2026

What is the current status of XENON XE-129 Hyperpolarized?

XENON XE-129 Hyperpolarized is an investigational imaging agent designed for magnetic resonance imaging (MRI). It uses hyperpolarized xenon-129 gas to enhance MRI sensitivity, specifically for lung imaging and cerebral applications. The agent is in preclinical or early clinical development stages, with no formal FDA approval as of 2023.

What factors influence market adoption?

Regulatory pathway: XENON XE-129 faces a lengthy approval process. It requires an Investigational New Drug (IND) application, followed by phased clinical trials to establish safety and efficacy. The complexity of manufacturing hyperpolarized gases contributes to regulatory hurdles.

Scientific validation: The technology's adoption hinges on peer-reviewed evidence demonstrating superior diagnostic value over existing modalities. Currently, clinical data remains limited to small studies and pilot trials.

Market need: There is significant demand for advanced lung imaging, especially in COPD, asthma, and pulmonary fibrosis. The ability to provide detailed functional lung data offers a compelling value proposition.

Cost and infrastructure: The production of hyperpolarized gases requires specialized equipment (e.g., polarizers), increasing upfront costs. Adoption in medical centers depends on available infrastructure and reimbursement policies.

Competing technologies: Alternatives include PET imaging, CT scans, and traditional MRI. While these are mature, hyperpolarized MRI offers non-invasive, radiation-free imaging with real-time functional data, which remains a niche.

What are the estimated market size and growth prospects?

Global lung imaging market size: Valued at approximately USD 800 million in 2022, with an expected annual growth rate (CAGR) of 6% through 2030[1].

Hyperpolarized MRI market segment: A subset of the overall MRI market, expected to reach USD 150 million by 2025, growing at an estimated CAGR of 15%-20%[2].

Potential clinical applications and revenue streams

Application	Market Opportunity	Timeline	Estimated Adoption Rate (2023-2030)
Lung disease imaging	USD 100 million	3-5 years	10%-20%
Brain imaging	USD 50 million	4-6 years	5%-15%

Revenue projections: Initial revenues are expected to be modest, primarily from research collaborations and early clinical trials. Commercialization could generate USD 50 million to USD 150 million annually once widespread clinical adoption occurs, possibly around 2030[3].

What are key financial risks?

• Development costs: High expenses for device manufacturing, clinical testing, and regulatory compliance.
• Regulatory delay: Unpredictable approval timelines may extend time to market.
• Reimbursement: Lack of established reimbursement codes affects adoption.
• Market penetration: Limited initial applications may slow revenue growth.

Which companies and institutions are involved?

Primary stakeholders include:

• Xenon Medical Technologies: Developer of the hyperpolarization technology and clinical trial initiator.
• Academic medical centers: Conduct early research and validation studies.
• Regulatory agencies: FDA, European Medicines Agency (EMA) oversee approval process.
• Industry partners: Potential collaborators could include GE Healthcare, Siemens, and Philips that develop MRI systems capable of hyperpolarized gas imaging.

What is the outlook for investments and partnerships?

Investor interest depends on clinical trial outcomes and regulatory progress. Funding pathways include grants (e.g., from NIH), venture capital, and strategic partnerships with MRI device manufacturers. Collaborative agreements may accelerate commercialization and market entry.

Key Takeaways

• XENON XE-129 Hyperpolarized is in early developmen t, with limited clinical data.
• Market potential exists mainly in lung and brain imaging segments, with high growth prospects.
• Adoption depends on technological validation, regulatory approval, infrastructure readiness, and reimbursement policies.
• Revenue projections suggest modest initial returns, with considerable upsides post-market entry.
• Investment risks include high R&D costs, uncertain regulatory timelines, and slow market adoption.

FAQs

1. When could XENON XE-129 Hyperpolarized be commercially available?

Potentially in 5-7 years, contingent on successful clinical trials and regulatory approval.

2. What are the main technical challenges?

Producing stable, high-polarization levels at scale and integrating hyperpolarization technology into existing MRI systems.

3. How does hyperpolarized xenon compare to traditional MRI contrast agents?

It offers non-invasive, radiation-free imaging with functional insight, whereas traditional agents primarily provide structural data and involve contrast media risks.

4. Which diseases could benefit most from this technology?

Chronic obstructive pulmonary disease, asthma, and neurodegenerative diseases requiring detailed lung and brain imaging.

5. How significant is reimbursement for market success?

Crucial; without reimbursement policies, adoption in clinical practice may stall despite technical advantages.

References

[1] MarketsandMarkets. (2022). Lung imaging market forecast.
[2] IndustryARC. (2021). Hyperpolarized MRI market analysis.
[3] MedTech Outlook. (2022). Emerging hyperpolarized MRI capabilities.